國家衛生研究院 NHRI:Item 3990099045/2978
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 925101      線上人數 : 897
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/2978


    題名: A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy
    作者: Chen, YM;Shih, JF;Perng, RP;Tsai, CM;Whang-Peng, J
    貢獻者: National Institute of Cancer Research
    摘要: Study objective: Docetaxel has shown activity in the second-line treatment of non-small cell lung cancer (NSCLC). Phase II studies have suggested that weekly therapy with docetaxel probably has a better toxicity profile than the conventional schedule of once every 3 weeks. Our aim was to evaluate and compare the efficacy of different docetaxel schedules in NSCLC patients who did not respond to previous platinum-based chemotherapy. Setting: National teaching hospital in Taiwan. Methods: Treatment consisted of the following: (1) docetaxel, 35 mg/m(2) IV infusion (D-35) on days 1, 8, and 15 every 4 weeks; (2) docetaxel, 40 mg/m(2) IV (D-40) on days 1 and 8 every 3 weeks; and (3) docetaxel, 75 mg/m(2) IV (D-75) on day 1 every 3 weeks. Patients were randomized at a ratio of 2:2:1, with the D-75 arm as the control arm. From 2002 to 2004, 161 patients were enrolled into the study. Results: The number of patients enrolled in each arm of the study was as follows: D-35 group, 64 patients; D-40 group, 64 patients; D-75 group, 33 patients. The mean ages of patients were as follows: D-35 group, 65 years of age; D-40 group, 63 years of age; D-75 group, 64 years of age. The median number of cycles of chemotherapy received in each group was as follows: D-35 group, 4; D-40 group, 3; D-75 group, 4. The objective response rates were as follows: D-35 group, 17.2%; D-40 group, 10.9%; D-75 group, 6.1% (p = 0.615). The major toxicity was myelosuppression. Grades 3/4 leukopenia and neutropenia were significantly higher in the D-75 arm of the study (p < 0.001). Drug-induced pneumonitis occurred more frequently in patients on a weekly schedule than in those on a schedule of every 3-weeks (p = 0.05). The median survival times were as follows: D-35 group, 8.4 months; D-40 group, 7.2 months; and D-75 group, 9.5 months (p = 0.855). The 1-year survival rates were 32.8%, 31.9%, and 28.7%, respectively. Lung cancer symptom scores showed no obvious differences among the different treatment arms, except for some minor items. Conclusions: Weekly docetaxel chemotherapy produces less myelosuppression, and better compliance and response rates than the conventional chemotherapy administered every 3 weeks. These effects were more evident in the D-35 group weekly schedule than in the D-40 weekly, schedule. However, physicians should pay more attention to the possibility of a higher frequency of docetaxel-induced pneumonitis in patients receiving treatment on the weekly schedule of treatment.
    關鍵詞: Respiratory System
    日期: 2006-04
    關聯: Chest. 2006 Apr;129(4):1031-1038.
    Link to: http://dx.doi.org/10.1378/chest.129.4.1031
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0012-3692&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000236901000032
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33645983333
    顯示於類別:[彭汪嘉康(1996-2007)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    000236901000032.pdf447KbAdobe PDF654檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋